Adventrx Pharmaceuticals Inc Sample Contracts

AGREEMENT
Registration Rights Agreement • April 13th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
AutoNDA by SimpleDocs
Exhibit 4.23 SECURITIES PURCHASE AGREEMENT dated as of July 21, 2005,
Securities Purchase Agreement • August 12th, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
BACKGROUND
Registration Rights Agreement • June 30th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
RECITALS
Registration Rights Agreement • September 15th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
21,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT
Underwriting Agreement • July 13th, 2023 • Savara Inc • Pharmaceutical preparations • New York
BACKGROUND
Rights Agreement • August 12th, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
FIRST AMENDMENT TO LICENSE AGREEMENT
License Agreement • October 2nd, 2001 • Biokeys Pharmaceuticals Inc
COMMON STOCK PURCHASE WARRANT ADVENTRX PHARMACEUTICALS, INC.
Common Stock Purchase Warrant • November 14th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date, as listed above, and on or prior to the close of business on April 1, 2015 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued by the Company as of the date hereof pursuant to (i) Section A.2 of the Engagement Letter Agreement, dated May 17, 2011, between the Company and Rodman & Renshaw, LLC and (ii) Section 4(2) of the Securities Act an

MAST THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES
Indenture • March 24th, 2015 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York

INDENTURE, dated as of [—], 20[—], among MAST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 3rd, 2010 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of May 2, 2010, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

SAVARA INC. SHARES OF COMMON STOCK (PAR VALUE $0.001 PER SHARE) SALES AGREEMENT
Sales Agreement • July 6th, 2021 • Savara Inc • Pharmaceutical preparations • New York

SAVARA INC., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EVERCORE GROUP L.L.C. (the “Agent”) as follows:

MAST THERAPEUTICS, INC. SALES AGREEMENT
Sales Agreement • August 21st, 2015 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York

Mast Therapeutics, Inc. (the “Company”) confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as set forth below. This Agreement shall terminate and supersede that certain Sales Agreement, dated February 10, 2014, by and between the Company and Cowen (the “Prior Agreement”) as of the effective date of this Agreement and, upon entry into this Agreement, no further sales shall be made pursuant to the Prior Agreement.

AutoNDA by SimpleDocs
21,250,000 SHARES of Common Stock and 10,625,000 WARRANTS OF ADVENTRX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • November 14th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York

The undersigned, ADVENTRX Pharmaceuticals, Inc., a company formed under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of the Company, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters”) named in Schedule I hereto for whom Rodman & Renshaw, LLC is acting as representative (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

50,000,000 Units Each Unit Consisting of One Share of Common Stock And One Warrant to Purchase 0.5 of a Share of Common Stock Mast Therapeutics, Inc. PURCHASE AGREEMENT
Purchase Agreement • June 17th, 2013 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York

Mast Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 50,000,000 units (the “Firm Units”), each of which shall consist of (i) one (1) share of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”) (such shares of Common Stock constituting a part of the Units, collectively the “Shares”), and (ii) one warrant to purchase 0.5 of a share of Common Stock (such warrants constituting a part of the Units, collectively the “Warrants”). The Company has also granted to the Underwriters an option to purchase up to 7,500,000 additional units on the terms and for the purposes set forth in Section 3 hereof (the “Option Units”). The shares of Common Stock issuable upon exercise of the Warrants are called the “Warrant Shares,” and the Warrant Shares, together with the Warrants and the Shares, are called the “Securities.” The Firm Units and any Option Units purcha

STRICTLY CONFIDENTIAL Mr. Brian M. Culley Chief Business Officer Adventrx Pharmaceuticals Inc. 6725 Mesa Ridge Road Suite 100 San Diego, CA 92121 Dear Mr. Culley:
Adventrx Pharmaceuticals Inc • January 4th, 2010 • Pharmaceutical preparations • New York

This letter (the “Agreement”) constitutes the agreement between Adventrx Pharmaceuticals Inc. (the “Company”) and Rodman & Renshaw, LLC (“Rodman”) that Rodman shall serve as the exclusive placement agent (the “Services”) for the Company, on a “best efforts” basis, in connection with the proposed offer and placement (the “Offering”) by the Company of approximately $15.0 million of securities of the Company (the “Securities”), including convertible preferred securities. The terms of the Offering and the Securities shall be mutually agreed upon by the Company and the investors and nothing herein implies that Rodman would have the power or authority to bind the Company or an obligation for the Company to issue any Securities or complete the Offering. The Company expressly acknowledges and agrees that Rodman’s obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by Rodman to purchase the Securities and do

BY AND AMONG
Agreement and Plan of Merger • October 2nd, 2001 • Biokeys Pharmaceuticals Inc • Delaware
29,090,910 UNITS, EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK, OF MAST THERAPEUTICS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • February 11th, 2016 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York

The undersigned, Mast Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Mast Therapeutics, Inc. (the “Company”)), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and, each, an “Underwriter”) named in Schedule I hereto for which Roth Capital Partners, LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • January 7th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2011, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Time is Money Join Law Insider Premium to draft better contracts faster.